HepaFatSmart's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for HepaFatSmart. Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| HepaFatSmart | Resonance Health Limited | Diagnostic Device | Approved | 0 | ||||
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | 89bio, Inc. | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | 89bio, Inc. | — | Phase 3 | — | — | — | — | — |
| A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH | Neuraly, Inc. | — | Phase 2 | — | — | — | — | — |
| Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Ain Shams University | — | Phase 2 | — | — | — | — | — |
| Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | AB Biotics, SA | — | Phase 2 | — | — | — | — | — |